Medical Oncology

, 36:13 | Cite as

HIV-associated cancers: the role of a unique multidisciplinary board to optimize patient’s care behalf the CANCERVIH Group

  • Aurelien Gobert
  • Jean-Philippe SpanoEmail author
  • Jacques Cadranel
Letter to the Editor


Since 1996, the life expectancy of people living with HIV (PLWHIV) has improved, while their risk of cancer is 2–3 times higher than in the general population. HIV-associated cancers remain a critical issue in this population and represent a particular care challenge due to the high risk of drug interactions and additive toxicity. The new standards of care with immunotherapy will also become a major issue for PLWHIV because of the potential impact on immunology and virology. Thus, the National Cancer Institute created the CANCERVIH national network in 2014 in France, enabling the establishment of a multidisciplinary national board of experts. This is an important first step that will help patients and health professionals provide optimal treatment to PLWHIV and prevent disparities. We hope that such a multidisciplinary council will make its voice heard in other countries and that this could be useful for patients with HIV-related cancers.


HIV Cancer Healthcare 



We thank Marianne Veyri and the CANCERVIH Group members for their work and implication in PWHIV cancer care.


CANCERVIH group is supported and funded by the French INCA (Institut National du Cancer).

Compliance with ethical standards

Conflict of interest

Aurelien Gobert received fees from Pfizer, MSD, Astellas and Roche for participating to board of experts. Jean-Philippe Spano, consultant for Roche and MSD, has received a speaker honorarium from Roche, AZ, MSD, Gilead, Pfizer, BMS, Lilly, PFO, Leopharma and Myriad Genetics. Jacques Cadranel received fees from AZ, BI, BMS, MSD, Novartis Pfizer, Roche and Takeda fort participating to board of experts; received grants for his institution for research programs from AZ, BI, Novartis and Pfizer.

Ethical approval

All procedures performed involving human participants in our study were in accordance with the ethical standards of the Institutional and/or research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards [our group has received an approval from the Commission Nationale de l’Informatique et des Libertés (CNIL), n°16-391].


  1. 1.
    Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65(4):636–43.CrossRefGoogle Scholar
  2. 2.
    Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(11):1029–41.CrossRefGoogle Scholar
  3. 3.
    Spano J-P, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(3):397–408.CrossRefGoogle Scholar
  4. 4.
    Suneja G, Lin CC, Simard EP, Han X, Engels EA, Jemal A. Disparities in cancer treatment among patients infected with the human immunodeficiency virus. Cancer. 2016;122(15):2399–407.CrossRefGoogle Scholar
  5. 5.
    Lavolé A, Guihot A, Veyri M, Lambotte O, Autran B, Cloarec N, et al. PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy? Ann Oncol Off J Eur Soc Med Oncol. 2018;29(4):1065–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Aurelien Gobert
    • 1
  • Jean-Philippe Spano
    • 1
    • 2
    Email author
  • Jacques Cadranel
    • 3
  1. 1.Pitie-Salpetriere HospitalSorbonne UniversityParisFrance
  2. 2.INSERM, UMRS 1136ParisFrance
  3. 3.Tenon HospitalSorbonne UniversityParisFrance

Personalised recommendations